TraceLink NEXUS 17 Attendees Cite Information Sharing as Largest Benefit Expected from End-to-End Visibility of Pharmaceutical Supply Chain

NORTH READING, Mass., June 29, 2017 /PRNewswire/ -- TraceLink Inc., the World's Largest Track and Trace Network for connecting the life sciences supply chain and providing real-time information sharing for better patient outcomes, announces new industry findings from its annual conference, NEXUS 17. Interactive polling results indicated that the majority of pharmaceutical supply chain professionals (78 percent of attendees), believe that end-to-end visibility of pharmaceutical products in the supply chain is achievable within the next five years, with information sharing between trading partners cited as one of the most valuable business benefits.

At NEXUS 17 in Barcelona earlier this month, TraceLink introduced its strategy for leveraging the industry's only digital supply chain network to facilitate a new era of real-time information sharing, addressing a critical information gap that has existed for decades between pharmaceutical companies, pharmacists and patients. The first application unveiled within this road map, the Pharmacy Compliance and Digital Information Platform, enables any EU pharmacy to easily comply with verification and decommissioning requirements under the Falsified Medicines Directive (FMD), while simultaneously delivering a real-time dashboard for insights into pharmacy operations and enabling a direct communication channel from the pharmaceutical manufacturer to the pharmacy.

As the premier venue for the convergence of the pharmaceutical supply chain, NEXUS 17 drew more than 200 pharmaceutical supply chain professionals and business leaders, representing over 120 unique companies from 21 different countries. The conference included educational content from 30 speakers, including esteemed keynote speaker, Dr. Bertalan Mesko – "The Medical Futurist" and experts from Sanofi, Santen, Recipharm, Tjoapack, MIT and the European Medicines Verification Organisation (EMVO). Attendees participated in live interactive polling throughout the two days, sharing their own insights and perspective on the topics covered in the keynotes, breakout sessions, and roundtable workshops.

"There is tremendous value in connecting companies and trade partners together in an educational forum, allowing everyone to equally learn from collective wisdom. This year, NEXUS truly showcased the power of the network in the pharmaceutical supply chain – demonstrated through inspirational keynotes, dynamic breakout and roundtable discussions, and high attendee engagement during the networking sessions," said Shabbir Dahod, president and CEO, TraceLink.  "As serialization deadlines fall into place, now is the time to leverage the foundation of an integrated network in order to enhance real-time communication and information exchange between all of the partners in the supply chain. From the very beginning, TraceLink has been architected with true interconnectedness, and by enabling the flow of serialization data between over 260,000 trade partners on our network, is the only provider that can deliver the next step of capabilities by taking information and moving it end-to-end across the supply chain."

In addition to discussions around achieving valuable benefits beyond compliance, NEXUS 17 attendees also responded to questions about serialization preparation, challenges, and trade partner readiness, indicating the following:

• Nearly one-half (48 percent) of respondents preparing for serialization indicated they are most worried about the exchange of information. Testing and validation of systems (21 percent) is also a top concern among polling respondents.
• The greatest serialization challenge thus far, among NEXUS 17 attendees, has been line vendors' inability to deliver a solution on time and within scope (47 percent). The second most cited challenge was lack of Level 3 functionality and flexibility to fulfill business requirements in the solution (26 percent).
• When asked about relationships with their contract manufacturing organization (CMO) and contract packaging organization (CPO) partners, sixty eight percent of pharmaceutical companies that responded, felt their CMOs and/or CPOs are not well prepared to meet serialization requirements. Eighty nine percent of respondents believe their CMOs should integrate serialization into their current packaging lines with data management.

To access the full polling data results from NEXUS 17, download the Serialization Snapshot: The Current State of Readiness.

For those that missed NEXUS 17, photos and keynote slide presentations are available at www.nexus-tracelink.com.

About TraceLink
TraceLink is the World's Largest Track and Trace Network for connecting the life sciences supply chain and eliminating counterfeit prescription drugs from the global marketplace. Leading businesses trust the TraceLink Life Sciences Cloud to deliver complete global connectivity, visibility and traceability of pharmaceuticals from ingredient to patient. A single point and click connection to the Life Sciences Cloud creates a supply chain control tower that delivers the information, insight and collaboration needed to improve performance and reduce risk across global supply, manufacturing and distribution operations. A winner of numerous industry awards including Deloitte's Technology Fast 500 (ranked number 149 in 2016), the Amazon AWS Global Start-Up Challenge Grand Prize, and the Edison Award for Innovation in Health Management, the Life Sciences Cloud is used by businesses across the globe to meet strategic goals in ensuring global compliance, fighting drug counterfeiting, improving on-time and in-full delivery, protecting product quality and reducing operational cost. For more information on TraceLink and our solutions, visit www.tracelink.com or follow us on LinkedIn, Twitter and Facebook.

TraceLink is funded by Goldman Sachs, FirstMark Capital, Volition Capital and F-Prime Capital.

SOURCE TraceLink

Related Links

http://www.tracelink.com